Education
About Us
Working with TipRanks
Follow Us
Q32 Bio (QTTB)
NASDAQ:QTTB
QTTB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.35 - $53.17
Previous CloseN/A
Volume113.57K
Average Volume (3M)87.19K
Market Cap
$22.81M
Enterprise Value-$17.96M
Total Cash (Recent Filing)$54.83M
Total Debt (Recent Filing)$18.70M
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Nov 06, 2025EPS Estimate
-1.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.78
Shares Outstanding12,197,615
10 Day Avg. Volume73,248
30 Day Avg. Volume87,185
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.79
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit197.37
Enterprise Value/Ebitda0.57
Forecast
1Y Price Target
$10.00Price Target Upside434.76% Upside
Rating ConsensusHold
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe first patients have been dosed in Part B and the open-label extension of Part A of the Phase 2 SIGNAL-AA trial of bempikibart in alopecia areata.
Patient OutcomesAll patients who completed Part A treatment maintained hair after 36 weeks and beyond, with some achieving additional hair growth post-treatment.
Bears Say
Comparative EfficacyBempi's recent AAD update shows a reduction in SALT, but the data is still inferior to JAKs in alopecia areata trials.
Financial ChallengesQTTB will likely need to raise cash to move bempi forward in alopecia areata, indicating financial challenges ahead.
Q32 Bio News
QTTB FAQ
What was Q32 Bio’s price range in the past 12 months?
Q32 Bio lowest stock price was $1.34 and its highest was $53.17 in the past 12 months.
What is Q32 Bio’s market cap?
Q32 Bio’s market cap is $22.81M.
When is Q32 Bio’s upcoming earnings report date?
Q32 Bio’s upcoming earnings report date is Nov 06, 2025 which is in 41 days.
How were Q32 Bio’s earnings last quarter?
Q32 Bio released its earnings results on Aug 06, 2025. The company reported -$0.78 earnings per share for the quarter, beating the consensus estimate of -$0.978 by $0.198.
Is Q32 Bio overvalued?
According to Wall Street analysts Q32 Bio’s price is currently Undervalued.
Does Q32 Bio pay dividends?
Q32 Bio does not currently pay dividends.
What is Q32 Bio’s EPS estimate?
Q32 Bio’s EPS estimate is -1.19.
How many shares outstanding does Q32 Bio have?
Q32 Bio has 12,197,615 shares outstanding.
What happened to Q32 Bio’s price movement after its last earnings report?
Q32 Bio reported an EPS of -$0.78 in its last earnings report, beating expectations of -$0.978. Following the earnings report the stock price went down -1.515%.
Which hedge fund is a major shareholder of Q32 Bio?
Currently, no hedge funds are holding shares in QTTB
Q32 Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$10.00 (434.76% Upside)
$10.00 (434.76% Upside)
Blogger Sentiment
Bullish
QTTB Sentiment 100%
Sector Average 73%
Sector Average 73%
Insider Transactions
Sold Shares
Worth $31.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-95.78%
12-Months-Change
Fundamentals
Return on Equity
-491.67%
Trailing 12-Months
Asset Growth
-46.77%
Trailing 12-Months
Company Description
Q32 Bio
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.
Technical Analysis
Tempest Therapeutics
―
Chemomab Therapeutics
―
Annovis Bio
―
Passage Bio
―
Cognition Therapeutics
―
Ownership Overview
2.55% Insiders
4.31% Mutual Funds
64.44% Other Institutional Investors
26.39% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---